Authors' recommendations: Ramipril oral solution is recommended as an option for use within NHS Wales for: - Treatment of hypertension. - Cardiovascular prevention: reduction of cardiovascular morbidity and mortality in patients with: - manifest atherothrombotic cardiovascular disease (history of coronary heart disease or stroke, or peripheral vascular disease); - diabetes with at least one cardiovascular risk factor. - Treatment of renal disease: - incipient glomerular diabetic nephropathy as defined by the presence of macroalbuminuria; - manifest glomerular diabetic nephropathy as defined by macroproteinuria in patients with at least one cardiovascular risk factor; - manifest glomerular non diabetic nephropathy as defined by macroproteinuria = 3 g/day. - Treatment of symptomatic heart failure. - Secondary prevention after acute myocardial infarction: reduction of mortality from the acute phase of myocardial infarction in patients with clinical signs of heart failure when started > 48 hours following acute myocardial infarction.

Project Status: Completed

Year Published: 2012

URL for published report: http://www.wales.nhs.uk/sites3/Documents/371/ramipril%20oral%20solution%20FAR.pdf

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: Wales, United Kingdom

Organisation Name: All Wales Medicines Strategy Group

Contact Address: All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX

Contact Name: AWTTC@wales.nhs.uk

Contact Email: AWTTC@wales.nhs.uk

Copyright: AWTTC